Crispr Therapeutics Ag (CRSP)

EBITDA

-$454.02M

TTM · Period ending: · USD

CRSP logo

CRSP EBITDA

Latest reported-$454.02M
CRSP TTM EBITDA (-$25.54M → -$454.02M)
High-resolution chart · PNG

CRSP ebitda history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Crispr Therapeutics Ag EBITDA — Trailing twelve months (TTM) (USD)
Period endingEBITDA (USD)
-454,016,000
-546,108,000
-558,486,000
-465,917,000
-444,855,000
-362,523,000
-343,406,000
-217,157,000
-243,645,000
-195,225,000
-130,885,000
-339,570,000
-402,861,000
-503,452,000
-626,328,000
-644,857,001
-597,175,001
342,292,999
400,034,999
427,574,000
459,934,000
-385,584,000
-345,251,000
-227,641,000
2,869,000
27,581,000
51,465,000
-11,986,000
-200,981,000
-183,617,000
-162,177,000
-109,363,000
-83,592,000
-67,771,000
-61,624,000
-86,300,000
-77,971,000
-74,364,000
-66,032,000
-55,192,000
-46,896,000
-33,514,000
-25,544,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.